360 related articles for article (PubMed ID: 25710562)
1. A novel dual AMPK activator/mTOR inhibitor inhibits thyroid cancer cell growth.
Plews RL; Mohd Yusof A; Wang C; Saji M; Zhang X; Chen CS; Ringel MD; Phay JE
J Clin Endocrinol Metab; 2015 May; 100(5):E748-56. PubMed ID: 25710562
[TBL] [Abstract][Full Text] [Related]
2. Targeting energy metabolic and oncogenic signaling pathways in triple-negative breast cancer by a novel adenosine monophosphate-activated protein kinase (AMPK) activator.
Lee KH; Hsu EC; Guh JH; Yang HC; Wang D; Kulp SK; Shapiro CL; Chen CS
J Biol Chem; 2011 Nov; 286(45):39247-58. PubMed ID: 21917926
[TBL] [Abstract][Full Text] [Related]
3. Role of AMP-activated protein kinase activators in antiproliferative multi-drug pituitary tumour therapies: effects of combined treatments with compounds affecting the mTOR-p70S6 kinase axis in cultured pituitary tumour cells.
Tulipano G; Faggi L; Cacciamali A; Spinello M; Cocchi D; Giustina A
J Neuroendocrinol; 2015 Jan; 27(1):20-32. PubMed ID: 25323047
[TBL] [Abstract][Full Text] [Related]
4. Belinostat-induced apoptosis and growth inhibition in pancreatic cancer cells involve activation of TAK1-AMPK signaling axis.
Wang B; Wang XB; Chen LY; Huang L; Dong RZ
Biochem Biophys Res Commun; 2013 Jul; 437(1):1-6. PubMed ID: 23743198
[TBL] [Abstract][Full Text] [Related]
5. The influence of the BRAF V600E mutation in thyroid cancer cell lines on the anticancer effects of 5-aminoimidazole-4-carboxamide-ribonucleoside.
Choi HJ; Kim TY; Chung N; Yim JH; Kim WG; Kim JA; Kim WB; Shong YK
J Endocrinol; 2011 Oct; 211(1):79-85. PubMed ID: 21795305
[TBL] [Abstract][Full Text] [Related]
6. Compound C induces protective autophagy in cancer cells through AMPK inhibition-independent blockade of Akt/mTOR pathway.
Vucicevic L; Misirkic M; Janjetovic K; Vilimanovich U; Sudar E; Isenovic E; Prica M; Harhaji-Trajkovic L; Kravic-Stevovic T; Bumbasirevic V; Trajkovic V
Autophagy; 2011 Jan; 7(1):40-50. PubMed ID: 20980833
[TBL] [Abstract][Full Text] [Related]
7. Metformin inhibits growth and decreases resistance to anoikis in medullary thyroid cancer cells.
Klubo-Gwiezdzinska J; Jensen K; Costello J; Patel A; Hoperia V; Bauer A; Burman KD; Wartofsky L; Vasko V
Endocr Relat Cancer; 2012 Jun; 19(3):447-56. PubMed ID: 22389381
[TBL] [Abstract][Full Text] [Related]
8. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
[TBL] [Abstract][Full Text] [Related]
9. TMP21 modulates cell growth in papillary thyroid cancer cells by inducing autophagy through activation of the AMPK/mTOR pathway.
Xu X; Gao H; Qin J; He L; Liu W
Int J Clin Exp Pathol; 2015; 8(9):10824-31. PubMed ID: 26617795
[TBL] [Abstract][Full Text] [Related]
10. The AMPK Agonist PT1 and mTOR Inhibitor 3HOI-BA-01 Protect Cardiomyocytes After Ischemia Through Induction of Autophagy.
Huang L; Dai K; Chen M; Zhou W; Wang X; Chen J; Zhou W
J Cardiovasc Pharmacol Ther; 2016 Jan; 21(1):70-81. PubMed ID: 25868658
[TBL] [Abstract][Full Text] [Related]
11. The mTOR Kinase Inhibitor CZ415 Inhibits Human Papillary Thyroid Carcinoma Cell Growth.
Li X; Li Z; Song Y; Liu W; Liu Z
Cell Physiol Biochem; 2018; 46(2):579-590. PubMed ID: 29617677
[TBL] [Abstract][Full Text] [Related]
12. 2-Arylthiazolidine-4-carboxylic acid amides (ATCAA) target dual pathways in cancer cells: 5'-AMP-activated protein kinase (AMPK)/mTOR and PI3K/Akt/mTOR pathways.
Li CM; Narayanan R; Lu Y; Hurh E; Coss CC; Barrett CM; Miller DD; Dalton JT
Int J Oncol; 2010 Oct; 37(4):1023-30. PubMed ID: 20811725
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-451 regulates AMPK/mTORC1 signaling and fascin1 expression in HT-29 colorectal cancer.
Chen MB; Wei MX; Han JY; Wu XY; Li C; Wang J; Shen W; Lu PH
Cell Signal; 2014 Jan; 26(1):102-9. PubMed ID: 23899558
[TBL] [Abstract][Full Text] [Related]
14. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro.
Liu H; Scholz C; Zang C; Schefe JH; Habbel P; Regierer AC; Schulz CO; Possinger K; Eucker J
Anticancer Res; 2012 May; 32(5):1627-37. PubMed ID: 22593441
[TBL] [Abstract][Full Text] [Related]
15. Metformin inhibits thyroid cancer cell growth, migration, and EMT through the mTOR pathway.
Han B; Cui H; Kang L; Zhang X; Jin Z; Lu L; Fan Z
Tumour Biol; 2015 Aug; 36(8):6295-304. PubMed ID: 25854169
[TBL] [Abstract][Full Text] [Related]
16. Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway.
Lin CC; Yeh HH; Huang WL; Yan JJ; Lai WW; Su WP; Chen HH; Su WC
Am J Respir Cell Mol Biol; 2013 Aug; 49(2):241-50. PubMed ID: 23526220
[TBL] [Abstract][Full Text] [Related]
17. Involvement of mTOR and Regulation by AMPK in Early Iodine Deficiency-Induced Thyroid Microvascular Activation.
Craps J; Joris V; De Jongh B; Sonveaux P; Horman S; Lengelé B; Bertrand L; Many MC; Colin IM; Gérard AC
Endocrinology; 2016 Jun; 157(6):2545-59. PubMed ID: 27035650
[TBL] [Abstract][Full Text] [Related]
18.
Jiménez-Mora E; Gallego B; Díaz-Gago S; Lasa M; Baquero P; Chiloeches A
Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34204950
[TBL] [Abstract][Full Text] [Related]
19. Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells.
Din FV; Valanciute A; Houde VP; Zibrova D; Green KA; Sakamoto K; Alessi DR; Dunlop MG
Gastroenterology; 2012 Jun; 142(7):1504-15.e3. PubMed ID: 22406476
[TBL] [Abstract][Full Text] [Related]
20. Cation-selective transporters are critical to the AMPK-mediated antiproliferative effects of metformin in human breast cancer cells.
Cai H; Zhang Y; Han TK; Everett RS; Thakker DR
Int J Cancer; 2016 May; 138(9):2281-92. PubMed ID: 26669511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
